ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析

◆英語タイトル:ProQR Therapeutics NV (PRQR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH452686FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber’s congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer’s disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV Key Recent Developments

Mar 02,2021: ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
Feb 25,2021: ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
Nov 16,2020: ProQR announces third quarter 2020 operating and financial results
Oct 05,2020: ProQR appoints Naveed Shams, MD, PhD as Chief Scientific Officer
Aug 06,2020: ProQR announces second quarter 2020 operating and financial results

This comprehensive SWOT profile of ProQR Therapeutics NV provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ProQR Therapeutics NV including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ProQR Therapeutics NV – Key Information
ProQR Therapeutics NV – Overview
ProQR Therapeutics NV – Key Employees
ProQR Therapeutics NV – Key Employee Biographies
ProQR Therapeutics NV – Key Operational Heads
ProQR Therapeutics NV – Major Products and Services
ProQR Therapeutics NV – History
ProQR Therapeutics NV – Company Statement
ProQR Therapeutics NV – Locations And Subsidiaries
ProQR Therapeutics NV
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ProQR Therapeutics NV – Business Description
ProQR Therapeutics NV – Corporate Strategy
ProQR Therapeutics NV – SWOT Analysis
SWOT Analysis – Overview
ProQR Therapeutics NV – Strengths
ProQR Therapeutics NV – Weaknesses
ProQR Therapeutics NV – Opportunities
ProQR Therapeutics NV – Threats
ProQR Therapeutics NV – Key Competitors

Section 3 – Company Financial Performance Charts

ProQR Therapeutics NV – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ProQR Therapeutics NV, Key Information
ProQR Therapeutics NV, Key Ratios
ProQR Therapeutics NV, Share Data
ProQR Therapeutics NV, Major Products and Services
ProQR Therapeutics NV, History
ProQR Therapeutics NV, Key Employees
ProQR Therapeutics NV, Key Employee Biographies
ProQR Therapeutics NV, Key Operational Heads
ProQR Therapeutics NV, Other Locations
ProQR Therapeutics NV, Subsidiaries
ProQR Therapeutics NV, Key Competitors
ProQR Therapeutics NV, SWOT Analysis
ProQR Therapeutics NV, Ratios based on current share price
ProQR Therapeutics NV, Annual Ratios
ProQR Therapeutics NV, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • State Atomic Energy Corporation Rosatom-エネルギー分野:企業M&A・提携分析
    Summary State Atomic Energy Corporation Rosatom (ROSATOM), the Russian Federation national nuclear corporation, is a nuclear company that integrates nuclear companies and R&D institutions which operate in the civilian and defense sectors. It provides a variety of nuclear services that range from ura …
  • EGYPTAIR Holding Company:企業の戦略・SWOT・財務分析
    EGYPTAIR Holding Company - Strategy, SWOT and Corporate Finance Report Summary EGYPTAIR Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …
  • Ameren Corporation (AEE):電力:M&Aディール及び事業提携情報
    Summary Ameren Corporation (Ameren) is a public utility holding company that generates, transmits and distributes electricity; and transmits and distributes natural gas through its subsidiaries. The company generates electricity through varied energy sources such as coal, nuclear, hydro, solar, natu …
  • Interface Biologics Inc:製品パイプライン分析
    Summary Interface Biologics Inc (IBI) is a developer transformative biomedical polymer technology. The company offers anti-thrombogenic and combination drug delivery devices. Its blood contacting medical devices uses Endexo technology address problems related to thrombosis. IBI’s technologies includ …
  • TC BioPharm Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TC BioPharm Ltd (TC BioPharm) is an immunotherapy company that develops cell based products for treatment of cancer and viral infection. The company pipeline products are intended for the treatment of ovarian cancer, breast cancer and epidermolysisbullosa related disease, among others. It wo …
  • Precision Optics Corporation Inc (PEYE)-医療機器分野:企業M&A・提携分析
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company offers custom optics solutions such as design and prototyping, fib …
  • ShotSpotter Inc (SSTI):企業の財務・戦略的SWOT分析
    ShotSpotter Inc (SSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • TECSYS Inc. (TCS):企業の財務・戦略的SWOT分析
    TECSYS Inc. (TCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Interpace Diagnostics Group Inc (IDXG):医療機器:M&Aディール及び事業提携情報
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform. It …
  • PT Bank Bukopin Tbk:企業の戦略・SWOT・財務分析
    PT Bank Bukopin Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Bukopin Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Lanxess AG:企業の戦略・SWOT・財務情報
    Lanxess AG - Strategy, SWOT and Corporate Finance Report Summary Lanxess AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Bauhaus International (Holdings) Limited (483):企業の財務・戦略的SWOT分析
    Bauhaus International (Holdings) Limited (483) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Wolfgang Puck Worldwide Inc:企業の戦略・SWOT・財務分析
    Wolfgang Puck Worldwide Inc - Strategy, SWOT and Corporate Finance Report Summary Wolfgang Puck Worldwide Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Siemens Gamesa Renewable Energy S.A.:企業の戦略・SWOT・財務情報
    Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report Summary Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Miele & Cie. KG:企業の戦略的SWOT分析
    Miele & Cie. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Re-Vana Therapeutics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Re-Vana Therapeutics Ltd (Re-Vana) is an ocular pharmaceutical and drug delivery company that develops and commercialization of biodegradable long- acting drug delivery platforms to treat ophthalmic conditions. The company provides drug delivery products such as OcuLief, an injectable platfo …
  • Turkiye IS Bankasi A.S.:戦略・SWOT・企業財務分析
    Turkiye IS Bankasi A.S. - Strategy, SWOT and Corporate Finance Report Summary Turkiye IS Bankasi A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SunTrust Banks Inc:企業の戦略・SWOT・財務情報
    SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report Summary SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • 3E sanv:企業の戦略的SWOT分析
    3E sanv - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆